share_log

XOMA Corporation Announces Closing of Tender Offer

XOMA Corporation Announces Closing of Tender Offer

XOMA 公司宣佈收購結束
GlobeNewswire ·  04/03 21:00

Kinnate Stockholders to Receive $2.5879 Per Share in Cash Plus Contingent Value Right

Kinnate股東將獲得每股2.5879美元的現金加上或有價值權利

EMERYVILLE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) ("XOMA" or the "Company"), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health, today announced the Company has successfully completed its previously announced tender offer to acquire all outstanding shares of Kinnate Biopharma Inc. (NASDAQ: KNTE) common stock for a price per share of $2.5879 in cash (the "Cash Amount"), plus one non-tradeable contingent value right ("CVR" and together with the Cash Amount, the "Offer Price") representing the right to receive 85% of the net proceeds from any out license or sale of Kinnate programs effected within one year of closing of the merger and 100% of the net proceeds resulting from Kinnate's sale of exarafenib and other pan-RAF program assets to Pierre Fabre Laboratories, as announced on March 1, 2024.

加利福尼亞州埃默裏維爾,2024年4月3日(GLOBE NEWSWIRE)——在幫助生物技術公司實現改善人類健康目標方面發揮獨特作用的生物技術特許權使用費彙總商XOMA公司(納斯達克股票代碼:XOMA)(“XOMA” 或 “公司”)今天宣佈,該公司已成功完成先前宣佈的收購Kinnate Biopharma Inc.(納斯達克股票代碼:KNTE)所有已發行股份的要約普通股每股價格爲2.5879美元的現金(“現金金額”),外加一項不可交易的或有價值權利(“CVR”),以及現金金額,“要約價格”),代表在合併完成後一年內獲得任何許可或出售Kinnate計劃的淨收益的85%的權利,以及Kinnate於2024年3月1日宣佈的向皮爾法伯實驗室出售艾沙拉非尼和其他泛英國皇家空軍計劃資產所得淨收益的100%。

The tender offer and related withdrawal rights expired one minute after 11:59 p.m. Eastern Time on Tuesday, April 2, 2024 (the "Expiration Date"). As of the Expiration Date, a total of 38,258,681 shares of Kinnate common stock were validly tendered, and not validly withdrawn, representing approximately 81% of the outstanding shares of Kinnate common stock as of the Expiration Date. As of the Expiration Date, the number of shares validly tendered in accordance with the terms of the tender offer and not validly withdrawn satisfied the minimum tender condition, and all other conditions to the tender offer were satisfied or waived. Immediately after the Expiration Date, XOMA irrevocably accepted for payment all shares validly tendered and not validly withdrawn and expects to promptly pay for such shares.

要約和相關的提款權在東部時間2024年4月2日星期二晚上 11:59(“到期日”)一分鐘後到期。截至到期日,共有38,258,681股Kinnate普通股進行了有效投標,但未有效撤回,約佔截至到期日Kinnate普通股已發行股份的81%。截至到期日,根據要約條款有效投標但未有效撤回的股票數量滿足了最低投標條件,要約的所有其他條件均得到滿足或免除。到期日過後,XOMA立即不可撤銷地接受了所有已有效投標但未有效撤回的股份的付款,並期望立即支付此類股票。

Following the closing of the tender offer, XOMA merged Kinnate with and into a subsidiary, XRA 1 Corp. (the "Merger"), and all shares of Kinnate common stock that had not been validly tendered were converted into the right to receive the Offer Price. As a result of the Merger, Kinnate became a wholly owned subsidiary of XOMA. Prior to the opening of trading on The Nasdaq Stock Market LLC ("Nasdaq") on April 3, 2024, all shares of Kinnate common stock will cease trading on Nasdaq, and Kinnate intends promptly to cause such shares to be delisted from Nasdaq and deregistered under the Securities Exchange Act of 1934, as amended.

要約結束後,XOMA將Kinnate與子公司XRA 1 Corp.(“合併”)合併爲子公司,所有未經有效投標的Kinnate普通股均轉換爲獲得要約價格的權利。合併後,Kinnate成爲XOMA的全資子公司。在納斯達克股票市場有限責任公司(“納斯達克”)於2024年4月3日開盤交易之前,Kinnate普通股的所有股票將在納斯達克停止交易,Kinnate打算立即使此類股票從納斯達克退市,並根據經修訂的1934年《證券交易法》註銷註冊。

Advisors
XOMA was represented by Gibson, Dunn & Crutcher LLP. Leerink Partners acted as lead financial advisor and Wilson Sonsini Goodrich & Rosati acted as legal counsel to Kinnate. Lazard also acted as a financial advisor to Kinnate.

顧問
XOMA 由 Gibson、Dunn & Crutcher LLP 代理。Leerink Partners擔任首席財務顧問,威爾遜·桑西尼·古德里奇和羅薩蒂擔任Kinnate的法律顧問。拉扎德還曾擔任Kinnate的財務顧問。

About XOMA Corporation
XOMA is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of milestone and royalty assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit .

關於 XOMA 公司
XOMA是一家生物技術特許權使用費彙總商,在幫助生物技術公司實現改善人類健康的目標方面發揮着獨特的作用。XOMA收購了與已獲得製藥或生物技術公司許可的商業前候選療法相關的潛在未來經濟學。當XOMA收購未來經濟時,賣方將獲得非稀釋性、無追索權的資金,可用於推進其內部候選藥物或用於一般公司用途。該公司擁有廣泛且不斷增長的里程碑資產和特許權使用費資產組合(資產定義爲獲得與潛在候選療法發展相關的潛在未來經濟的權利)。有關公司及其投資組合的更多信息,請訪問 。

EXPLANATORY NOTE: Any references to "portfolio" in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. Any references to "assets" in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development.

解釋性說明:本新聞稿中任何提及 “投資組合” 的內容都嚴格指與正在開發的一攬子藥品相關的里程碑和/或特許權使用費。本新聞稿中任何提及 “資產” 的內容都嚴格指與正在開發的個別藥物產品相關的里程碑和/或特許權使用費。

About Kinnate Biopharma Inc.
Kinnate Biopharma Inc. is a clinical-stage precision oncology company founded with a mission to inspire hope in those battling cancer by expanding on the promise of targeted therapies. Kinnate concentrates its efforts on addressing known oncogenic drivers for which there are currently no approved targeted therapies and to overcome the limitations associated with existing cancer therapies, such as non-responsiveness or the development of acquired and intrinsic resistance.

關於 Kinnate Biopharma Inc.
Kinnate Biopharma Inc. 是一家臨床階段的精準腫瘤學公司,成立的使命是通過擴大靶向療法的前景來激發抗癌者的希望。Kinnate專注於解決目前尚無批准的靶向療法的已知致癌驅動因素,並克服與現有癌症療法相關的侷限性,例如無反應性或獲得性和內在耐藥性的發展。

Forward-Looking Statements/Explanatory Notes
Certain statements contained in this press release are forward-looking statements, including statements regarding the payment and timing of payment of the Offer Price to former Kinnate common stockholders and the ability and timing of delisting of Kinnate's common stock. In some cases, you can identify such forward-looking statements by terminology such as "anticipate," "approximately," "expect," "may," "will," "could" or "should," the negative of these terms or similar expressions. These forward-looking statements are not a guarantee of XOMA's performance, and you should not place undue reliance on such statements. These statements are based on assumptions that may not prove accurate, and actual results could differ materially from those anticipated due to certain risks including the risk that XOMA does not achieve anticipated net cash after winding down Kinnate's operations and concluding remaining clinical trial activities, the risk that XOMA is unable to develop or otherwise enter into dispositions related to the Kinnate programs, and risks that the timing of the payment or delisting may be delayed. Other potential risks to XOMA meeting these expectations are described in more detail in XOMA's most recent filing on Form 10-K and in other filings with the Securities and Exchange Commission, which are available on the SEC's website at www.sec.gov. Any forward-looking statement in this press release represents XOMA's beliefs and assumptions only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. XOMA disclaims any obligation to update any forward-looking statement, except as required by applicable law.

前瞻性陳述/解釋性說明
本新聞稿中包含的某些陳述是前瞻性陳述,包括有關向前Kinnate普通股股東支付要約價和支付時間以及Kinnate普通股退市的能力和時機的陳述。在某些情況下,您可以通過諸如 “預期”、“大約”、“預期”、“可能”、“將”、“可能” 或 “應該” 等術語來識別此類前瞻性陳述,這些術語的否定詞或類似表述。這些前瞻性陳述不能保證XOMA的表現,您不應過分依賴此類陳述。這些陳述基於可能不準確的假設,由於某些風險,實際結果可能與預期存在重大差異,包括XOMA在Kinnate結束業務和結束剩餘臨床試驗活動後無法實現預期淨現金的風險,XOMA無法制定或以其他方式進行與Kinnate計劃相關的處置的風險,以及付款或退市時間可能延遲的風險。XOMA最近提交的10-K表以及向美國證券交易委員會提交的其他文件中詳細描述了XOMA滿足這些預期的其他潛在風險,這些文件可在美國證券交易委員會的網站上查閱 www.sec.gov。本新聞稿中的任何前瞻性陳述僅代表XOMA截至本新聞稿發佈之日的信念和假設,不應以此作爲其後任何日期的觀點的依據。除非適用法律要求,否則XOMA不承擔任何更新任何前瞻性陳述的義務。

XOMA Investor Contact XOMA Media Contact
Juliane Snowden Kathy Vincent
XOMA Corporation KV Consulting & Management
+1 646-438-9754 +1 310-403-8951
juliane.snowden@xoma.com kathy@kathyvincent.com
XOMA 投資者聯繫方式 XOMA 媒體聯繫人
朱麗安·斯諾登 凱西·文森特
XOMA 公司 KV 諮詢與管理
+1 646-438-9754 +1 310-403-8951
juliane.snowden@xoma.com kathy@kathyvincent.com

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論